Get 40% Off
🚀 Our AI Picked 6 Stocks that Jumped +25% in Q1. Which Picks Will Soar in Q2?Unlock full list

Studies suggest Pfizer shot may protect only partially against Omicron

Published 12/07/2021, 04:11 PM
Updated 12/08/2021, 07:01 AM
© Reuters. FILE PHOTO: Vials of the Pfizer-BioNTech vaccine are pictured in a vaccination centre in Geneva, Switzerland, February 3, 2021. REUTERS/Denis Balibouse

(Raises paragraphs on global alarms)

By Michael Erman and Ludwig Burger

(Reuters) - The Omicron variant can partially evade protection from two doses of Pfizer (NYSE:PFE) and partner BioNTech's COVID-19 vaccine, the research head of a laboratory at the Africa Health Research Institute in South Africa said on Tuesday.

But the study showed that blood from people who had received two doses of the vaccine and had a prior infection was mostly able to neutralize the variant, suggesting that booster doses of the vaccine could help to fend off infection.

The Omicron variant, first detected in southern Africa last month, has triggered alarms globally of another surge in infections, with more than two dozen countries from Japan to the United States reporting cases.

The World Health Organization classified it on Nov. 26 as a "variant of concern," but said there was no evidence to support the need for new vaccines specifically designed to tackle the Omicron variant with its many mutations.

Alex Sigal, a professor at the research institute, said on Twitter (NYSE:TWTR) there was "a very large drop" in neutralization of the Omicron variant relative to an earlier strain of COVID-19.

A separate lab test by virologist Sandra Ciesek of the University Hospital Frankfurt painted a somewhat bleaker picture.

Exposing the blood of vaccinated individuals to different virus variants, she found that the ability to mount an antibody response to Omicron in people who had three shots of BioNTech/Pfizer was up to 37 times lower than the response to Delta.

An antibody response to Omicron half a year after a two-shot regimen of Pfizer/BioNTech, Moderna (NASDAQ:MRNA) or a mixed course of AstraZeneca/BioNTech was not even measurable, Ciesek added.

She posted only selected findings on Twitter, not including the number of samples, and the university said the paper had not yet been published.

"The set of data underscores that it makes sense to develop a vaccine that is adapted to Omicron," Chiesek tweeted, adding that no conclusion could be drawn about protection against severe disease.

WHO's chief scientist, Soumya Swaminathan, said a large drop in the antibody response of vaccinated people to Omicron had been expected.

"This does not mean the vaccine will not work - T-cell immunity (is) likely to persist," she said on Twitter, referring to a cellular immune response that is believed to prevent severe disease as a second line of immune defence.

Researchers including Carsten Watzl of the German Society of Immunology and Penny Ward, visiting professor at King’s College London, said the findings underscored the need to get booster shots because a three-shot course would likely continue to protect against severe disease.

Sigal's lab tested blood from 12 people who had been vaccinated with two doses of the Pfizer/BioNTech vaccine, according to a manuscript posted on the website for his lab. The preliminary data in the manuscript has not yet been peer reviewed.

Blood from five out of six people who had been vaccinated as well as previously infected with COVID-19 still neutralized the Omicron variant, the manuscript said.

"These results are better than I expected. The more antibodies you got, the more chance you'll be protected from Omicron," Sigal said on Twitter.

He said the lab had not tested the variant against blood from people who had received a booster dose, because they are not available in South Africa yet.

According to the manuscript, the lab observed a 41-fold decline in levels of neutralizing antibodies against the Omicron variant.

Sigal said on Twitter that figure is likely to be adjusted after his lab does more experiments.

While neutralizing antibodies are an indicator of the body's immune response, scientists believe other kinds of cells such as B-cells and T-cells are also stimulated by the vaccines and help protect against the effects of the coronavirus.

The preliminary data does not indicate that the vaccine is less able to prevent severe illness or death. While lab tests are under way, BioNTech CEO Ugur Sahin said last week "we think it's likely that people will have substantial protection against severe disease caused by Omicron".

© Reuters. A healthcare worker administers the Pfizer coronavirus disease (COVID-19) vaccine to Simphiwe, 13, amidst the spread of the SARS-CoV-2 variant Omicron in Johannesburg, South Africa, December 04, 2021. REUTERS/Sumaya Hisham

There is not significant data yet on how vaccines from Moderna, Johnson & Johnson (NYSE:JNJ) and other drugmakers hold up against the new variant. All the manufacturers, including Pfizer and BioNTech, are expected to release their own data within weeks.

BioNTech's Sahin told NBC News on Tuesday that the drugmaker has data coming on Wednesday or Thursday.

Latest comments

Coming soon in 2024, "5th booster for the 10th variation has been released and approved"
wait whaaa?
I need one shot of... whiskey. :)
What a farce. Proud & Unvaccinated
don’t worry. It is just taking you longer than normal to wake up. You will get there.
Real science tells us now that current vaccines do not prevent transmission
still? abort some babies
$PFE $BNTX Reportedly Pfizer and BioNTech announce three vaccine doses neutralize Omicron variant; 2-dose significantly less effective - press (Pfizer Inc)
you dont need protection vs a mild virus that make you immun, or you just stupid
For best investment advice read The Lancet and other medical journals; for best medical advice read the comments on investment.com.
Lol i love these people that talk about the science as if science is static
Another jab would "probably" work. Do you see a pattern here?
What an utterly confusing research or article, unsure !! If the virus will evade vaccine, then how the hell will booster shot help? Two, if it is able to evade the vaccine, which delta is unable to, then how in the world is it less riskier, infectious, virulent then delta, coz the chances of getting sick are higher even for the vaccines masses ?!!! Not sure if the idea of the article was to confuse if can't convince the world on how safe they are by just spending on the drugs the drug makers themselves say are NOT effective
What about the effectiveness of the Moderna vaccine which has 100 micrograms of the mRNA per injection as opposed to Pfizer’s 30 micrograms of the mRNA?  This is 21/3 times more micrograms of mRNA per iinjection than Pfizer, which should produce more antibodies and consequently, higher efficacy.
Does anyone really trust these people?
Its a cold. Doesnt matter
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.